ClinicalTrials.Veeva

Menu

Wide-Awake Local Anesthesia No Tourniquet (WALANT) With Versus Without Hyaluronidase for Hand Surgery

M

Misr University for Science and Technology

Status and phase

Enrolling
Phase 3
Phase 2

Conditions

Hand Surgery

Treatments

Drug: lidocaine 1 % mixture
Drug: Hyaluronidase and Lidocaine 1% mixture

Study type

Interventional

Funder types

Other

Identifiers

NCT07000058
2022/0103

Details and patient eligibility

About

The WALANT (Wide Awake Local Anesthesia No Tourniquet) method, introduced by Dr. Donald H. Lalonde over a decade ago, has gained popularity due to its favorable outcomes and patient satisfaction. This technique involves injecting diluted lidocaine and epinephrine, which helps control pain and bleeding without the discomfort of a tourniquet.

This research will explore the use of hyaluronidase to enhance the WALANT technique. The study hypothesize that adding hyaluronidase would improve the onset speed and duration of pain control. A double-blinded study involving 100 patients compared WALANT with hyaluronidase (Group A) to WALANT without Hyaluronidase (Group B).

Full description

Background: Hand surgery, being one of the most frequent outpatient procedures, remains undecided regarding the ideal anesthesia technique. Wide-Awake Local Anesthesia No Tourniquet (WALANT) is one of the frequently used anesthesia techniques by some hand surgeons (8%).

Objective: The study aims to evaluate the impact of hyaluronidase administration on the onset and persistence of WALANT in hand surgery.

Patients and Methods: This Prospective, randomized, double-blind clinical trial will be conducted in Souad Kafafi University Hospital (SKUH), faculty of medicine, Misr University for Science and Technology (MUST).

One hundred patients (18-60years old) with ASA class I or II who will be scheduled for hand surgery. They will be equally divided into two groups: Group A (n =50) WALANT with hyaluronidase technique: Patients will receive a mixture of hyaluronidase 15 IU to every 1 ml lidocaine 1% mixture. Group B (n =50) WALANT without hyaluronidase technique: Patients will receive a mixture of lidocaine 1%. The infiltrative local anesthesia will be administered at the appropriate site in subcutaneous tissue just deep to the incisional site to produce tumescent local anesthesia. The onset time and duration of postoperative analgesia will be recorded.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • One hundred individuals scheduled for hand surgery between the ages of 18 and 60 years old, of both sexes and American Society of Anesthesiologists (ASA) classification I or II. were randomized 1:1 to either Group A; (Receiving WALANT with hyaluronidase) or Group B; (Receiving WALANT without hyaluronidase).

Exclusion criteria

  • Pregnant women, patients who refused the terms of the research consent statement, psychiatric illness, uncooperative patient, patients with history of allergy to local anesthetic drugs, cardiac arrhythmia, patients with bleeding tendency, patients with low flow finger perfusion state such as Burger disease and Raynaud's disease, patients with connective tissue disease such as Scleroderma and suspicious disease with malignancy and hand infection

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

100 participants in 2 patient groups

Group A (n=50): WALANT with Hyaluronidase
Experimental group
Description:
Patients received a mixture of hyaluronidase 15 IU to every 1 ml lidocaine 1% mixture (a solution composed of epinephrine 1:200,000 and lidocaine 1%). Buffered to reduce injection pain by 1 ml of sodium bicarbonate 8.4% for every 10 ml of the local anesthetic mixture.
Treatment:
Drug: Hyaluronidase and Lidocaine 1% mixture
Group B (n=50): WALANT without Hyaluronidase:
Active Comparator group
Description:
A mixture of epinephrine 1:200,000 and lidocaine 1% buffered to reduce injection pain by 1 ml of sodium bicarbonate 8.4% for every 10 ml of the local anesthetic mixture.
Treatment:
Drug: lidocaine 1 % mixture

Trial contacts and locations

1

Loading...

Central trial contact

E. L. M. Ahmed, Anesth. lectur.; Ahmed Aly El komy, Anesth.Resid.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems